

Taylor Morrisette

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2919024/taylor-morrisette-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

10,804
citations

44
h-index

102
g-index

186
ext. papers

13,063
ext. citations

5.7
avg, IF

6.43
L-index

#	Paper	IF	Citations
175	Therapeutic Strategies for Emerging Multidrug-Resistant <i>Pseudomonas aeruginosa</i> .. <i>Infectious Diseases and Therapy</i> , 2022 , 11, 661	6.2	6
174	How to Harness the Power of Social Media for Quality Drug Information in Infectious Diseases: Perspectives on Behalf of the Society of Infectious Diseases Pharmacists.. <i>Clinical Infectious Diseases</i> , 2022 , 74, e23-e33	11.6	1
173	Novel Combination Therapy for Extensively Drug-Resistant Necrotizing Pneumonia Complicated by Empyema: A Case Report.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofac092	1	1
172	Eradication of Biofilm-Mediated Methicillin-Resistant <i>Staphylococcus aureus</i> Infections : Bacteriophage-Antibiotic Combination.. <i>Microbiology Spectrum</i> , 2022 , e0041122	8.9	4
171	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Bloodstream Infection.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab606	1	1
170	Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19.. <i>Infectious Diseases and Therapy</i> , 2022 , 1	6.2	0
169	Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens.. <i>Infectious Diseases and Therapy</i> , 2022 , 1	6.2	0
168	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
167	Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin Against Daptomycin-Nonsusceptible. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0162321	5.9	2
166	Questions on Vancomycin Dosing. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1777-e1778	11.6	1
165	Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant <i>Staphylococcus aureus</i> Complicated Skin and Soft Tissue Infections. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4560-e4567	11.6	4
164	Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2486-2488	5.1	2
163	Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Bacteremia: STAPH Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab261	1	2
162	In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant. <i>Antibiotics</i> , 2021 , 10,	4.9	4
161	Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant and. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab371	1	8
160	Novel approaches for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> : Using nanoparticles to overcome multidrug resistance. <i>Drug Discovery Today</i> , 2021 , 26, 31-43	8.8	16
159	Preliminary, Real-world, Multicenter Experience With Omadacycline for Infections. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab002	1	9

158	Impact of COVID-19 pandemic on training of pharmacy residents and fellows: Results from a national survey of postgraduate pharmacy trainees. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 1104-1111	2.2	2
157	Exebacase in Addition to Daptomycin against MRSA. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0012821	5.9	2
156	Antibacterial Activity of Cefiderocol against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0264620	5.9	6
155	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 93-113	6.2	9
154	Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab554	1	5
153	Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of in a Pharmacokinetic/Pharmacodynamic Model. <i>Antibiotics</i> , 2020 , 9,	4.9	7
152	Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	17
151	Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. <i>Pharmacotherapy</i> , 2020 , 40, 648-658	5.8	11
150	A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant <i>Staphylococcus aureus</i> bacteremia complicated by septic pulmonary emboli. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 2199-2203	5.3	4
149	Bacteriophage-Antibiotic Combinations for <i>Enterococcus faecium</i> with Varying Bacteriophage and Daptomycin Susceptibilities. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	9
148	Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β -Lactam Combinations Against Daptomycin-Resistant <i>Enterococcus faecium</i> . <i>Journal of Infectious Diseases</i> , 2020 , 222, 1531-1539	5.7	2
147	Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, the Society of Infectious Disease Pharmacists, and the Society of Hospital Pharmacists. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64, e00815-20	2.2	307
146	Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa051	1	23
145	Combinations of (lipo)glycopeptides with β -lactams against MRSA: susceptibility insights. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2894-2901	5.1	6
144	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime-Avibactam. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 291-304	6.2	6
143	Early Experience With Eravacycline for Complicated Infections. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa071	1	11
142	Evaluation of Eravacycline: A Novel Fluorocycline. <i>Pharmacotherapy</i> , 2020 , 40, 221-238	5.8	17
141	A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 89-106	6.2	11

140	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy, Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review. Pharmacotherapy, 2020, 40, 469-478</i>	5.8	26
139	Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β -Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis. <i>Infectious Diseases and Therapy, 2020, 9, 325-339</i>	6.2	13
137	Opportunities for antimicrobial stewardship among carbapenem-treated patients in 18 North American hospitals. <i>International Journal of Antimicrobial Agents, 2020, 55, 105970</i>	14.3	2
136	Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections. <i>Antimicrobial Agents and Chemotherapy, 2020, 64,</i>	5.9	25
135	Multicenter Cohort of Patients With Methicillin-Resistant Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. <i>Open Forum Infectious Diseases, 2020, 7, ofz538</i>	1	30
134	Bacteriophage Therapeutics: A Primer for Clinicians on Phage-Antibiotic Combinations. <i>Pharmacotherapy, 2020, 40, 153-168</i>	5.8	29
133	Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens. <i>Pharmacotherapy, 2020, 40, 1228-1247</i>	5.8	15
132	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases, 2020, 71, 1361-1364</i>	11.6	55
131	Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Journal of the</i>	4.8	20
130	The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination Therapy. <i>Antibiotics, 2020, 9,</i>	4.9	8
129	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <i>Infectious Diseases and Therapy, 2020, 9, 561-572</i>	6.2	15
128	Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy, 2020, 65,</i>	5.9	5
127	Daptomycin Plus β -Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. <i>Clinical Infectious Diseases, 2020, 71, 1-10</i>	11.6	39
126	The Emerging Role of β -Lactams in the Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy, 2020, 64,</i>	5.9	12
125	Impact of Daptomycin Dose Exposure Alone or in Combination with β -Lactams or Rifampin against Vancomycin-Resistant Enterococci in an Biofilm Model. <i>Antimicrobial Agents and Chemotherapy, 2020, 64,</i>	5.9	6
124	Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide. <i>Pharmacotherapy, 2019, 39, 1077-1094</i>	5.8	10
123	Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of in a Simulated Pharmacodynamic/Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy, 2019, 63,</i>	5.9	14

122	Long-Acting Lipoglycopeptides: "Lineless Antibiotics" for Serious Infections in Persons Who Use Drugs. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz274	1	27
121	Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	52
120	Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
119	Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	12
118	On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 2405-2416	5.1	36
117	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz077	1	6
116	Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 155-170	6.2	9
115	Reply to Koehler et al. <i>Clinical Infectious Diseases</i> , 2019 , 69, 901-902	11.6	1
114	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019 , 69, 903-904	11.6	0
113	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz079	1	8
112	Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against <i>Streptococcus mitis</i> in an Simulated Endocarditis Vegetation Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
111	A new simplified predictive model for mortality in methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 843-850	5.3	2
110	Oral Vancomycin Prophylaxis as Secondary Prevention Against <i>Clostridioides difficile</i> Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2091-2097	4.7	16
109	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 346-350	14.3	5
108	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 627-640	6.2	6
107	Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Skin and Soft Tissue Infections. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 229-242	6.2	3
106	1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Bloodstream Infections (BSI). <i>Open Forum Infectious Diseases</i> , 2019 , 6, S582-S582	1	78
105	Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz522	1	41

104	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1650-1657	11.6	22
103	Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 489-498	5.1	21
102	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 75-85	6.2	1
101	Mutations in and Correlate with Daptomycin Resistance in and. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	10
100	Evaluation of dalbavancin alone and in combination with β -lactam antibiotics against resistant phenotypes of Staphylococcus aureus. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 82-86	5.1	10
99	Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 161-169	6.2	6
98	A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2018 , 67, 303-309	11.6	92
97	Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 197-217	6.2	51
96	β -Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	30
95	Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an Model of Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
94	Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018 , 51, 43-46	14.3	5
93	Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	72
92	Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA. <i>Materials</i> , 2018 , 11,	3.5	12
91	Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 135-146	6.2	11
90	Making the change to area under the curve-based vancomycin dosing. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1986-1995	2.2	53
89	Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 3529-3531	5.1	6
88	Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β -Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	16
87	Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	5

86	Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 363-370	2.9	10
85	Perturbations of Phosphatidate Cytidyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	30
84	Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence. <i>Pharmacotherapy</i> , 2017 , 37, 579-592	5.8	50
83	Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2290-2296	5.1	13
82	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	41
81	Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017 , 89, 61-66	2.9	22
80	Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017 , 89, 324-327	2.9	5
79	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	126
78	β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
77	Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. <i>Clinical Infectious Diseases</i> , 2017 , 64, 116-123	11.6	114
76	Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12
75	Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 152-5	5.1	54
74	Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 367-77	6.2	7
73	Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6609-6618	5.9	19
72	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5841-8	5.9	38
71	Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5716-23	5.9	27
70	Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2352-8	5.9	19
69	Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections. <i>Infectious Diseases and Therapy</i> , 2016 , 5, 1-15	6.2	55

68	Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion?. <i>American Journal of Infection Control</i> , 2016 , 44, 47-9	3.8	3
67	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1242-1250	11.6	64
66	Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 1708-16	5.9	24
65	Comparison of clinical outcomes and risk factors in polymicrobial versus monomicrobial enterococcal bloodstream infections. <i>American Journal of Infection Control</i> , 2016 , 44, 917-21	3.8	6
64	Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3743-50	5.9	47
63	Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3970-5	5.9	14
62	β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1738-43	5.1	75
61	Examining the use of ceftaroline in the treatment of Streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2428-31	5.9	14
60	Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5529-34	5.9	18
59	Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2978-85	5.9	47
58	Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1969-76	5.9	27
57	β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2842-8	5.9	32
56	Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 245-58	6.2	57
55	Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. <i>Circulation</i> , 2015 , 132, 1435-86	16.7	1479
54	Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 311-3	5.1	34
53	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 505-9	5.1	30
52	Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1584-91	5.9	16
51	Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 519-28	6.2	8

50	Global Antimicrobial Stewardship: Challenges and Successes from Frontline Stewards. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 1-3	6.2	7
49	Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. <i>Pharmacotherapy</i> , 2015 , 35, 935-48	5.8	33
48	The β -Lactams Strike Back: Ceftazidime-Avibactam. <i>Pharmacotherapy</i> , 2015 , 35, 755-70	5.8	113
47	Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant <i>Staphylococcus aureus</i> with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4497-503	5.9	29
46	Nephrotoxicity comparison of two commercially available generic vancomycin products. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5470-4	5.9	15
45	Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. <i>Journal of Emergency Medicine</i> , 2015 , 48, 508-19	1.5	72
44	Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 489-93	5.1	30
43	Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1272-3	5.1	1
42	Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. <i>Clinical Therapeutics</i> , 2014 , 36, 1317-33	3.5	118
41	Potent synergy of ceftobiprole plus daptomycin against multiple strains of <i>Staphylococcus aureus</i> with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3006-10	5.1	36
40	Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant <i>Staphylococcus aureus</i> in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3177-81	5.9	35
39	Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2541-6	5.9	84
38	Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4636-41	5.9	11
37	Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3968-75	5.9	20
36	A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Infectious Diseases and Therapy</i> , 2014 , 3, 69-81	6.2	20
35	A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2989-92	5.9	29
34	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2148-54	5.1	45
33	Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. <i>Infectious Diseases and Therapy</i> , 2014 , 3, 35-43	6.2	52

32	Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2014 , 19, 135-40	1.6	8
31	Letter from the editor. <i>Infectious Diseases and Therapy</i> , 2013 , 2, 81-2	6.2	
30	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4252-4259	5.9	58
29	Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 66-73	5.9	98
28	Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect". <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2664-8	5.9	48
27	Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5768-74	5.9	28
26	Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3174-80	5.9	76
25	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. <i>Clinical Infectious Diseases</i> , 2011 , 52, e18-55	11.6	1736
24	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. <i>Clinical Infectious Diseases</i> , 2011 , 52, 285-92	11.6	1209
23	Reply to Cataldo et al. <i>Clinical Infectious Diseases</i> , 2011 , 53, 310-310	11.6	
22	Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2009 , 49, 325-7	11.6	566
21	In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4712-7	5.9	69
20	Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2009 , 29, 1275-9	5.8	207
19	Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). <i>Journal of Clinical Microbiology</i> , 2008 , 46, 2958-74	5.4	120
18	Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated methicillin-resistant and -susceptible S. aureus. <i>Journal of Medical Microbiology</i> , 2008 , 57, 452-456	3.2	11
17	Antimicrobial stewardship. <i>Pharmacotherapy</i> , 2007 , 27, 131S-135S	5.8	11
16	The pharmacokinetic and pharmacodynamic properties of vancomycin. <i>Clinical Infectious Diseases</i> , 2006 , 42 Suppl 1, S35-9	11.6	483
15	Pharmacodynamics: relation to antimicrobial resistance. <i>American Journal of Infection Control</i> , 2006 , 34, S38-45; discussion S64-73	3.8	42

14	Pharmacodynamics: relation to antimicrobial resistance. <i>American Journal of Medicine</i> , 2006 , 119, S37-44; discussion S62-70	2.4	53
13	Clinical isolates of <i>Staphylococcus aureus</i> from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 51, 119-25 ⁹	2.9	19
12	Community-associated methicillin-resistant <i>Staphylococcus aureus</i> : a review. <i>Pharmacotherapy</i> , 2005 , 25, 74-85	5.8	89
11	Daptomycin - a novel antibiotic against Gram-positive pathogens. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2321-31	4	55
10	Resistance to antimicrobial agents: an update. <i>Pharmacotherapy</i> , 2004 , 24, 203S-15S	5.8	32
9	Increased bacterial resistance: PROTEKT US--an update. <i>Annals of Pharmacotherapy</i> , 2004 , 38, S8-S13	2.9	8
8	Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant <i>Staphylococcus aureus</i> , vancomycin-resistant <i>Enterococcus faecium</i> , and methicillin-resistant <i>Staphylococcus aureus</i> isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 454-9	5.9	166
7	Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. <i>Expert Opinion on Emerging Drugs</i> , 2001 , 6, 43-55		5
6	Emergence of methicillin-resistant <i>Staphylococcus aureus</i> with intermediate glycopeptide resistance: clinical significance and treatment options. <i>Drugs</i> , 2001 , 61, 1-7	12.1	85
5	Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1921-4	5.9	32
4	In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against <i>Staphylococci</i> and <i>Enterococci</i> , including vancomycin- intermediate and -resistant strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1062-6	5.9	275
3	Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperzolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against <i>Staphylococcus aureus</i> , coagulase-negative staphylococci, <i>Enterococcus faecalis</i> , and <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 721-4	5.9	118
2	Ofloxacin clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1992 , 22, 32-46	6.2	31
1	Inhibition of drug metabolism by quinolone antibiotics. <i>Clinical Pharmacokinetics</i> , 1988 , 15, 194-204	6.2	62